Post
Lilly agrees to buy POINT Biopharma for $1.4bn
Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of radiopharmaceutical company POINT …
WHO’s SAGE recommends Takeda’s dengue vaccine
The World Health Organisation’s (WHO) Strategic Advisory Group of Experts (SAGE) has recommended Takeda’s QDENGA (dengue tetravalent vaccine [live, attenuated]) …
Nitric oxide by NOxy Health Products for Diabetic Foot Ulcers: Likelihood of Approval
Nitric oxide is under clinical development by NOxy Health Products and currently in Phase I for Diabetic Foot Ulcers. According …
Super DC Vaccine by Shanghai Cell Therapy Group for Solid Tumor: Likelihood of Approval
Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor. …
MC-232 by MC2 Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval
MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase …
Super DC Vaccine by Shanghai Cell Therapy Group for Solid Tumor: Likelihood of Approval
Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor. …
MC-232 by MC2 Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval
MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase …
CD123-targeted CAR-NK by Chongqing Precision Biotech for Natural Killer Cell Lymphomas: Likelihood of Approval
CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Natural Killer Cell Lymphomas. …
BGB-26808 by BeiGene for Solid Tumor: Likelihood of Approval
BGB-26808 is under clinical development by BeiGene and currently in Phase I for Solid Tumor. According to GlobalData, Phase I …
BGBA-3055 by BeiGene for Solid Tumor: Likelihood of Approval
BGBA-3055 is under clinical development by BeiGene and currently in Phase I for Solid Tumor. According to GlobalData, Phase I …
BW-20507 by Argo Biopharma Australia for Hepatitis B: Likelihood of Approval
BW-20507 is under clinical development by Argo Biopharma Australia and currently in Phase II for Hepatitis B. According to GlobalData, …
CT-080 by First Condor Group for Esophageal Cancer: Likelihood of Approval
CT-080 is under clinical development by First Condor Group and currently in Phase II for Esophageal Cancer. According to GlobalData, …
CT-080 by First Condor Group for Solid Tumor: Likelihood of Approval
CT-080 is under clinical development by First Condor Group and currently in Phase II for Solid Tumor. According to GlobalData, …
CT-080 by First Condor Group for Gastric Cancer: Likelihood of Approval
CT-080 is under clinical development by First Condor Group and currently in Phase II for Gastric Cancer. According to GlobalData, …
CT-080 by First Condor Group for Colorectal Cancer: Likelihood of Approval
CT-080 is under clinical development by First Condor Group and currently in Phase II for Colorectal Cancer. According to GlobalData, …